Filing Details

Accession Number:
0001209191-13-053161
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-11-19 17:17:04
Reporting Period:
2013-11-15
Filing Date:
2013-11-19
Accepted Time:
2013-11-19 17:17:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1172480 Santarus Inc SNTS Pharmaceutical Preparations (2834) 330734433
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1279191 T Gerald Proehl Santarus, Inc.
3611 Valley Centre Drive #400
San Diego CA 92130
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-11-15 56,644 $3.50 86,834 No 4 M Direct
Common Stock Disposition 2013-11-15 56,644 $0.00 30,190 No 4 G Direct
Common Stock Acquisiton 2013-11-15 56,644 $0.00 385,926 No 4 G Indirect By Family Trust
Common Stock Disposition 2013-11-15 56,644 $32.02 329,282 No 4 S Indirect By Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 G Direct
No 4 G Indirect By Family Trust
No 4 S Indirect By Family Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2013-11-15 56,644 $0.00 56,644 $3.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
56,643 2003-12-23 2013-12-23 No 4 M Direct
Footnotes
  1. This exercise and this sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 05/14/2013.
  2. This transaction involved a gift of securities by the reporting person to his family trust.
  3. By The Proehl Family Trust dtd 6/7/2007.
  4. The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.95 to $32.09. The reporting person undertakes to provide to Santarus, Inc., any security holder of Santarus, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
  5. Fully exercisable.